{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:07:50Z","timestamp":1777302470881,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,3,17]],"date-time":"2018-03-17T00:00:00Z","timestamp":1521244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["K2014-52X-14045-14-3"],"award-info":[{"award-number":["K2014-52X-14045-14-3"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"name":"l\u2019Association des M\u00e9decins Rhumatologues du Qu\u00e9bec","award":["Visithan-Khy Award"],"award-info":[{"award-number":["Visithan-Khy Award"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s11926-018-0726-4","type":"journal-article","created":{"date-parts":[[2018,3,17]],"date-time":"2018-03-17T01:49:51Z","timestamp":1521251391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["New Myositis Classification Criteria\u2014What We Have Learned Since Bohan and Peter"],"prefix":"10.1007","volume":"20","author":[{"given":"Val\u00e9rie","family":"Leclair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid E.","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,17]]},"reference":[{"issue":"8","key":"726_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403\u20137.","journal-title":"N Engl J Med"},{"issue":"7","key":"726_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344\u20137.","journal-title":"N Engl J Med"},{"issue":"3","key":"726_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/art.22003","volume":"55","author":"JA Singh","year":"2006","unstructured":"Singh JA, Solomon DH, Dougados M, Felson D, Hawker G, Katz P, et al. Development of classification and response criteria for rheumatic diseases. Arthritis Rheum. 2006;55(3):348\u201352.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"726_CR4","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.23015","volume":"57","author":"M Dougados","year":"2007","unstructured":"Dougados M, Gossec L. Classification criteria for rheumatic diseases: why and how? Arthritis Rheum. 2007;57(7):1112\u20135.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"726_CR5","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/art.23018","volume":"57","author":"SR Johnson","year":"2007","unstructured":"Johnson SR, Goek ON, Singh-Grewal D, Vlad SC, Feldman BM, Felson DT, et al. Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum. 2007;57(7):1119\u201333.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"726_CR6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/acr.22583","volume":"67","author":"R Aggarwal","year":"2015","unstructured":"Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken). 2015;67(7):891\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"726_CR7","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"\u2022\u2022 Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955\u201364. The new classification criteria for myositis are data driven, were developed in an international multidisciplinary collaboration and are based on a probability model. The variables are given different scores and the probability model gives a flexibility in number of variables needed to be tested to define a case as myositis and a subgroup of myositis.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"726_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/00005792-197707000-00001","volume":"56","author":"A Bohan","year":"1977","unstructured":"Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore). 1977;56(4):255\u201386.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"726_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0950-3579(05)80255-9","volume":"9","author":"CV Oddis","year":"1995","unstructured":"Oddis CV, Medsger TA,J. Inflammatory myopathies. Baillieres Clin Rheumatol. 1995;9(3):497\u2013514.","journal-title":"Baillieres Clin Rheumatol"},{"issue":"6","key":"726_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/00002281-199711000-00008","volume":"9","author":"IN Targoff","year":"1997","unstructured":"Targoff IN, Miller FW, Medsger TA Jr, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1997;9(6):527\u201335.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"726_CR11","first-page":"240","volume":"25","author":"EJ Yunis","year":"1971","unstructured":"Yunis EJ, Samaha FJ. Inclusion body myositis. Lab Investig. 1971;25(3):240\u20138.","journal-title":"Lab Investig"},{"issue":"1","key":"726_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1212\/WNL.28.1.8","volume":"28","author":"S Carpenter","year":"1978","unstructured":"Carpenter S, Karpati G, Heller I, Eisen A. Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology. 1978;28(1):8\u201317.","journal-title":"Neurology"},{"issue":"21","key":"726_CR13","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","volume":"325","author":"MC Dalakas","year":"1991","unstructured":"Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991;325(21):1487\u201398.","journal-title":"N Engl J Med"},{"issue":"1","key":"726_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","volume":"52","author":"M Satoh","year":"2017","unstructured":"Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol. 2017;52(1):1\u201319.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"726_CR15","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/WCO.0000000000000376","volume":"29","author":"O Benveniste","year":"2016","unstructured":"\u2022\u2022 Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol. 2016;29(5):662\u201373. The authors propose a novel clinico-serological classification with emphasis on MSA and MAA statuses.","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"726_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","volume":"70","author":"LA Love","year":"1991","unstructured":"Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70(6):360\u201374.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"726_CR17","first-page":"668","volume":"22","author":"K Tanimoto","year":"1995","unstructured":"Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol. 1995;22(4):668\u201374.","journal-title":"J Rheumatol"},{"issue":"5","key":"726_CR18","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ana.410380504","volume":"38","author":"RC Griggs","year":"1995","unstructured":"Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38(5):705\u201313.","journal-title":"Ann Neurol"},{"issue":"8","key":"726_CR19","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"726_CR20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1067\/mjd.2002.120621","volume":"46","author":"RD Sontheimer","year":"2002","unstructured":"Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46(4):626\u201336.","journal-title":"J Am Acad Dermatol"},{"issue":"9388","key":"726_CR21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971\u201382.","journal-title":"Lancet"},{"issue":"3","key":"726_CR22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1212\/WNL.61.3.316","volume":"61","author":"MF Meulen van der","year":"2003","unstructured":"van der Meulen MF, Bronner IM, Hoogendijk JE, Burger H, van Venrooij WJ, Voskuyl AE, et al. Polymyositis: an overdiagnosed entity. Neurology. 2003;61(3):316\u201321.","journal-title":"Neurology"},{"issue":"2","key":"726_CR23","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1212\/WNL.63.2.402","volume":"63","author":"WG Bradley","year":"2004","unstructured":"Bradley WG. Polymyositis: an overdiagnosed entity. Neurology. 2004;63(2):402. author reply 3","journal-title":"Neurology"},{"issue":"2","key":"726_CR24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1212\/WNL.63.2.402","volume":"63","author":"GJ Hengstman","year":"2004","unstructured":"Hengstman GJ, van Engelen BG. Polymyositis: an overdiagnosed entity. Neurology. 2004;63(2):402\u20133. author reply 3","journal-title":"Neurology"},{"issue":"2","key":"726_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1212\/WNL.63.2.402","volume":"63","author":"FW Miller","year":"2004","unstructured":"Miller FW, Rider LG, Plotz PH, Rutkove SB, Pestronk A, Wortmann RL, et al. Polymyositis: an overdiagnosed entity. Neurology. 2004;63(2):402; author reply 3\u20133.","journal-title":"Neurology"},{"issue":"3","key":"726_CR26","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1212\/WNL.61.3.288","volume":"61","author":"AA Amato","year":"2003","unstructured":"Amato AA, Griggs RC. Unicorns, dragons, polymyositis, and other mythological beasts. Neurology. 2003;61(3):288\u20139.","journal-title":"Neurology"},{"issue":"5","key":"726_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14(5):337\u201345.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"726_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/ana.410230111","volume":"23","author":"G Karpati","year":"1988","unstructured":"Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol. 1988;23(1):64\u201372.","journal-title":"Ann Neurol"},{"issue":"3","key":"726_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/0046-8177(89)90128-7","volume":"20","author":"AM Emslie-Smith","year":"1989","unstructured":"Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol. 1989;20(3):224\u201331.","journal-title":"Hum Pathol"},{"issue":"6","key":"726_CR30","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/BOR.0b013e32834bab42","volume":"23","author":"A Pestronk","year":"2011","unstructured":"Pestronk A. Acquired immune and inflammatory myopathies: pathologic classification. Curr Opin Rheumatol. 2011;23(6):595\u2013604.","journal-title":"Curr Opin Rheumatol"},{"issue":"10","key":"726_CR31","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.autrev.2016.07.023","volume":"15","author":"L Musset","year":"2016","unstructured":"Musset L, Allenbach Y, Benveniste O, Boyer O, Bossuyt X, Bentow C, et al. Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a large international multi-center study. Autoimmun Rev. 2016;15(10):983\u201393.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"726_CR32","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1002\/art.27572","volume":"62","author":"L Christopher-Stine","year":"2010","unstructured":"Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62(9):2757\u201366.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"726_CR33","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1002\/art.22164","volume":"54","author":"IN Targoff","year":"2006","unstructured":"Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682\u20139.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"726_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/joim.12451","volume":"280","author":"Z Betteridge","year":"2016","unstructured":"Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016;280(1):8\u201323.","journal-title":"J Intern Med"},{"issue":"6","key":"726_CR35","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/BOR.0000000000000329","volume":"28","author":"M Fujimoto","year":"2016","unstructured":"Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol. 2016;28(6):636\u201344.","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"726_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12016-015-8513-8","volume":"52","author":"H Gunawardena","year":"2017","unstructured":"Gunawardena H. The clinical features of myositis-associated autoantibodies: a review. Clin Rev Allergy Immunol. 2017;52(1):45\u201357.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"726_CR37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","volume":"84","author":"Y Troyanov","year":"2005","unstructured":"Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore). 2005;84(4):231\u201349.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"726_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/MD.0b013e31827ebba1","volume":"92","author":"C Fernandez","year":"2013","unstructured":"\u2022\u2022 Fernandez C, Bardin N, De Paula AM, Salort-Campana E, Benyamine A, Franques J, et al. Correlation of clinicoserologic and pathologic classifications of inflammatory myopathies: study of 178 cases and guidelines for diagnosis. Medicine (Baltimore). 2013;92(1):15\u201324. Further expand a clinico-serological approach considering overlap features and autoantibodies as core components.","journal-title":"Medicine (Baltimore)"},{"issue":"24","key":"726_CR39","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/MD.0000000000000222","volume":"93","author":"Y Troyanov","year":"2014","unstructured":"\u2022\u2022 Troyanov Y, Targoff IN, Payette MP, Raynauld JP, Chartier S, Goulet JR, et al. Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features. Medicine (Baltimore). 2014;93(24):318\u201332. Further expand a clinico-serological approach considering overlap features and autoantibodies as core components.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"726_CR40","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/art.40063","volume":"69","author":"JL Senecal","year":"2017","unstructured":"Senecal JL, Raynauld JP, Troyanov Y. Editorial: a new classification of adult autoimmune myositis. Arthritis Rheumatol. 2017;69(5):878\u201384.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"726_CR41","first-page":"767","volume":"31","author":"H Linklater","year":"2013","unstructured":"Linklater H, Pipitone N, Rose MR, Norwood F, Campbell R, Salvarani C, et al. Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol. 2013;31(5):767\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"726_CR42","doi-asserted-by":"publisher","first-page":"e004552","DOI":"10.1136\/bmjopen-2013-004552","volume":"4","author":"S Brady","year":"2014","unstructured":"\u2022 Brady S, Squier W, Sewry C, Hanna M, Hilton-Jones D, Holton JL. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. BMJ Open. 2014;4(4):e004552. Comprehensive review of sIBM clinical features and the evolution of sIBM diagnostic criteria.","journal-title":"BMJ Open"},{"issue":"5","key":"726_CR43","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","volume":"83","author":"TE Lloyd","year":"2014","unstructured":"Lloyd TE, Mammen AL, Amato AA, Weiss MD, Needham M, Greenberg SA. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014;83(5):426\u201333.","journal-title":"Neurology"},{"issue":"1","key":"726_CR44","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/joim.12480","volume":"280","author":"D Hilton-Jones","year":"2016","unstructured":"Hilton-Jones D, Brady S. Diagnostic criteria for inclusion body myositis. J Intern Med. 2016;280(1):52\u201362.","journal-title":"J Intern Med"},{"issue":"4\u20135","key":"726_CR45","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.autrev.2014.01.022","volume":"13","author":"M Mahler","year":"2014","unstructured":"Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev. 2014;13(4\u20135):367\u201371.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"726_CR46","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","volume":"13","author":"JC Lega","year":"2014","unstructured":"Lega JC, Fabien N, Reynaud Q, Durieu I, Durupt S, Dutertre M, et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev. 2014;13(9):883\u201391.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"726_CR47","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.semarthrit.2016.03.011","volume":"46","author":"E Trallero-Araguas","year":"2016","unstructured":"Trallero-Araguas E, Grau-Junyent JM, Labirua-Iturburu A, Garcia-Hernandez FJ, Monteagudo-Jimenez M, Fraile-Rodriguez G, et al. Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group. Semin Arthritis Rheum. 2016;46(2):225\u201331.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"726_CR48","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","volume":"73","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2014;73(1):227\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"726_CR49","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3899\/jrheum.161480","volume":"44","author":"J Shi","year":"2017","unstructured":"Shi J, Li S, Yang H, Zhang Y, Peng Q, Lu X, et al. Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol. 2017;44(7):1051\u20137.","journal-title":"J Rheumatol"},{"issue":"Suppl 11","key":"726_CR50","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1002\/acr.20532","volume":"63","author":"LG Rider","year":"2011","unstructured":"\u2022 Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S118\u201357. Large cross-sectional study confirming the increased mortality risk in IIM-related ILD.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"726_CR51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13075-017-1219-y","volume":"19","author":"H Andersson","year":"2017","unstructured":"\u2022 Andersson H, Kirkhus E, Garen T, Walle-Hansen R, Merckoll E, Molberg O. Comparative analyses of muscle MRI and muscular function in anti-synthetase syndrome patients and matched controls: a cross-sectional study. Arthritis Res Ther. 2017;19(1):17. Cross-sectional analyses of antisynthetase patients compared with healthy controls suggesting a complementary role for MRI in IIM assessment.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"726_CR52","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/mus.24307","volume":"51","author":"J Vlekkert Van De","year":"2015","unstructured":"\u2022 Van De Vlekkert J, Maas M, Hoogendijk JE, De Visser M, Van Schaik IN. Combining MRI and muscle biopsy improves diagnostic accuracy in subacute-onset idiopathic inflammatory myopathy. Muscle Nerve. 2015;51(2):253\u20138. Muscle MRI followed by muscle biopsies were performed on patients with subacute IIM onset. The authors found muscle MRI to be a useful diagnostic tool and guide for biopsy site selection.","journal-title":"Muscle Nerve"},{"issue":"5","key":"726_CR53","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.semarthrit.2016.11.001","volume":"46","author":"J Day","year":"2017","unstructured":"Day J, Patel S, Limaye V. The role of magnetic resonance imaging techniques in evaluation and management of the idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2017;46(5):642\u20139.","journal-title":"Semin Arthritis Rheum"},{"key":"726_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2016.02.017","volume":"433","author":"I Cavazzana","year":"2016","unstructured":"Cavazzana I, Fredi M, Ceribelli A, Mordenti C, Ferrari F, Carabellese N, et al. Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera. J Immunol Methods. 2016;433:1\u20135.","journal-title":"J Immunol Methods"},{"key":"726_CR55","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.semarthrit.2017.06.001","volume":"47","author":"C Bertolazzi","year":"2017","unstructured":"Bertolazzi C, Cutolo M, Smith V, Gutierrez M. State of the art on nailfold capillaroscopy in dermatomyosistis and polymyositis. Semin Arthritis Rheum. 2017;47:432\u201344.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"726_CR56","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","volume":"43","author":"DA Isenberg","year":"2004","unstructured":"Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford). 2004;43(1):49\u201354.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"726_CR57","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/art.40060","volume":"69","author":"LG Rider","year":"2017","unstructured":"\u2022\u2022 Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, et al. 2016 American College of Rheumatology\/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2017;69(5):911\u201323. Recently published clinical response criteria in juvenile DM.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"726_CR58","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","volume":"76","author":"R Aggarwal","year":"2017","unstructured":"\u2022\u2022 Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, et al. 2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2017;76(5):792\u2013801. Recently published clinical response criteria in adult IIM.","journal-title":"Ann Rheum Dis"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-018-0726-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0726-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0726-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,16]],"date-time":"2019-03-16T21:08:55Z","timestamp":1552770535000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-018-0726-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,17]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1007\/s11926-018-0726-4","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,17]]},"assertion":[{"value":"17 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Lundberg has received research grants from Bristol-Myers Squibb and from Astra-Zeneca and has served on advisory boards for Bristol-Myers Squibb and MedImmune.Dr. Leclair declares that she has no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"18"}}